Abrdn PLC Alkermes Plc. Transaction History

Abrdn PLC

$51.7 Billion
Q4 2024

A detailed history of Abrdn PLC transactions in Alkermes Plc. stock. As of the latest transaction made, Abrdn PLC holds 244,319 shares of ALKS stock, worth $8.39 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

244,319

Previous 392,542 37.76%

Holding current value

$8.39 Million

Previous $11 Million 36.05%

% of portfolio

0.01%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 24, 2025	SELL	$25.7 - $31.46 $3.81 Million - $4.66 Million	-148,223 Reduced 37.76%	244,319 $7.03 Million
Q3 2024 Oct 24, 2024	SELL	$23.01 - $28.55 $378,238 - $469,304	-16,438 Reduced 4.02%	392,542 $11 Million
Q2 2024 Aug 09, 2024	BUY	$23.21 - $27.24 $3.12 Million - $3.66 Million	134,213 Added 48.85%	408,980 $9.86 Million
Q1 2024 May 08, 2024	SELL	$26.4 - $32.56 $1.28 Million - $1.58 Million	-48,668 Reduced 15.05%	274,767 $7.44 Million
Q4 2023 Jan 31, 2024	BUY	$23.37 - $28.68 $7.56 Million - $9.28 Million	323,435 New	323,435 $8.97 Million
Q3 2019 Nov 13, 2019	SELL	$19.51 - $24.28 $402,335 - $500,702	-20,622 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$21.47 - $37.33 $12,194 - $21,203	568 Added 2.83%	20,622 $464,000
Q1 2019 May 14, 2019	BUY	$28.4 - $36.49 $332,365 - $427,042	11,703 Added 140.14%	20,054 $732,000
Q4 2018 Feb 12, 2019	SELL	$27.94 - $44.61 $2,402 - $3,836	-86 Reduced 1.02%	8,351 $242,000
Q3 2018 Nov 13, 2018	SELL	$38.6 - $46.12 $7,295 - $8,716	-189 Reduced 2.19%	8,437 $358,000
Q2 2018 Aug 09, 2018	BUY	$40.56 - $51.36 $349,870 - $443,031	8,626 New	8,626 $355,000

Others Institutions Holding ALKS

# of Institutions

376

Shares Held

173M

Call Options Held

231K

Put Options Held

158K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.64B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.

Account